{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:53:39Z","timestamp":1790384019321,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06075-2","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:26:44Z","timestamp":1730712404000},"page":"5539-5547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Sheeba Ba","family":"Aqeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman Salim","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragati","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"5","key":"6075_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J (2010) Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277\u2013300","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"6075_CR2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/bjh.15532","volume":"183","author":"KA Blum","year":"2018","unstructured":"Blum KA, Keller FG, Castellino S, Phan A, Flowers CR (2018) Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. Br J Haematol 183(3):385\u2013399","journal-title":"Br J Haematol"},{"issue":"6","key":"6075_CR3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjh.15734","volume":"185","author":"G Egan","year":"2019","unstructured":"Egan G, Goldman S, Alexander S (2019) Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol 185(6):1071\u20131085","journal-title":"Br J Haematol"},{"issue":"12","key":"6075_CR4","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","volume":"96","author":"S Mareschal","year":"2011","unstructured":"Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 96(12):1888\u20131890","journal-title":"Haematologica"},{"issue":"3","key":"6075_CR5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.21619","volume":"51","author":"RR Miles","year":"2008","unstructured":"Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ et al (2008) Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer 51(3):369\u2013374","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"6075_CR6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clml.2020.05.010","volume":"20","author":"D Blansky","year":"2020","unstructured":"Blansky D, Mantzaris I, Rohan T, Hosgood HD (2020) Influence of rurality, race, and ethnicity on Non-Hodgkin Lymphoma incidence. Clin Lymphoma Myeloma Leuk 20(10):668","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"46","key":"6075_CR7","doi-asserted-by":"crossref","first-page":"e17960","DOI":"10.1097\/MD.0000000000017960","volume":"98","author":"JS Guadamuz","year":"2019","unstructured":"Guadamuz JS, Ozenberger K, Qato DM, Ko NY, Saffore CD, Adimadhyam S et al (2019) Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. Medicine 98(46):e17960","journal-title":"Medicine"},{"key":"6075_CR8","doi-asserted-by":"publisher","unstructured":"Jin Y, Li J, Mun Y, Masaquel A, Hu S, Biondo JML et al (2021) Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): a U.S. real-world study using a de-identified electronic health record (EHR)-derived database.\u00a0J Clin Oncol 39(15_suppl):e18514-e18514. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e18514","DOI":"10.1200\/JCO.2021.39.15_suppl.e18514"},{"issue":"2","key":"6075_CR9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/10428194.2012.708751","volume":"54","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Shenoy PJ, Borate U, Bumpers K, Douglas-Holland T, King N et al (2013) Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma 54(2):268\u2013276","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6075_CR10","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/cncr.25765","volume":"117","author":"PJ Shenoy","year":"2011","unstructured":"Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW et al (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117(11):2530\u20132540","journal-title":"Cancer"},{"issue":"11","key":"6075_CR11","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood.V110.11.4430.4430","volume":"110","author":"A The","year":"2007","unstructured":"The A, Li Y, Reddy V, Davis R, Baird M, Foran J (2007) A comparative study of diffuse large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB). Blood 110(11):4430","journal-title":"Blood"},{"issue":"22","key":"6075_CR12","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V114.22.1392.1392","volume":"114","author":"PJ Shenoy","year":"2009","unstructured":"Shenoy PJ, Bumpers K, King N, Huang T, Malik N, Sinha R et al (2009) Black\/White differences in the treatment and outcomes of diffuse Large B Cell Lymphoma: A matched cohort analysis. Blood 114(22):1392","journal-title":"Blood"},{"issue":"16suppl","key":"6075_CR13","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2022.40.16_suppl.7507","volume":"40","author":"DA Ermann","year":"2022","unstructured":"Ermann DA, Vardell V, Fitzgerald L, Shah H, Stephens DM, Hu B (2022) Racial disparities affecting Black patients with diffuse large B-cell lymphoma. J Clin Oncol 40(16suppl):7507","journal-title":"J Clin Oncol"},{"issue":"12","key":"6075_CR14","doi-asserted-by":"crossref","first-page":"e2027738","DOI":"10.1001\/jamanetworkopen.2020.27738","volume":"3","author":"AR Scott","year":"2020","unstructured":"Scott AR, Stoltzfus KC, Tchelebi LT, Trifiletti DM, Lehrer EJ, Rao P et al (2020) Trends in Cancer Incidence in US adolescents and young adults, 1973\u20132015. Jama Netw Open 3(12):e2027738","journal-title":"Jama Netw Open"},{"key":"6075_CR15","doi-asserted-by":"crossref","first-page":"102044","DOI":"10.1016\/j.canep.2021.102044","volume":"75","author":"AM Berkman","year":"2021","unstructured":"Berkman AM, Andersen CR, Puthenpura V, Livingston J, Ahmed S, Cuglievan B et al (2021) Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. Cancer Epidemiol 75:102044","journal-title":"Cancer Epidemiol"},{"issue":"22","key":"6075_CR16","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027\u20135033","journal-title":"J Clin Oncol"},{"issue":"5","key":"6075_CR17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"key":"6075_CR18","first-page":"101","volume":"6","author":"F Ederer","year":"1961","unstructured":"Ederer F (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101\u2013121","journal-title":"Natl Cancer Inst Monogr"},{"issue":"5","key":"6075_CR19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","volume":"181","author":"N Epperla","year":"2018","unstructured":"Epperla N, Hamadani M, Fenske TS, Costa LJ (2018) Incidence and survival trends in mantle cell lymphoma. Br J Haematol 181(5):703\u2013706","journal-title":"Br J Haematol"},{"issue":"14","key":"6075_CR20","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ejca.2011.03.011","volume":"47","author":"T Hakulinen","year":"2011","unstructured":"Hakulinen T, Sepp\u00e4 K, Lambert PC (2011) Choosing the relative survival method for cancer survival estimation. Eur J Cancer 47(14):2202\u20132210","journal-title":"Eur J Cancer"},{"issue":"15","key":"6075_CR21","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1002\/cam4.3237","volume":"9","author":"N Epperla","year":"2020","unstructured":"Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ (2020) Recent survival trends in diffuse large B-cell lymphoma\u2013Have we made any progress beyond rituximab? Cancer Med 9(15):5519\u20135525","journal-title":"Cancer Med"},{"issue":"6","key":"6075_CR22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/jayao.2018.0034","volume":"7","author":"JC Avila","year":"2018","unstructured":"Avila JC, Livingston JA, Rodriguez AM, Kirchhoff AC, Kuo Y-F, Kaul S (2018) Disparities in adolescent and young adult sarcoma survival: analyses of the Texas cancer registry and the national SEER data. J Adolesc young adult Oncol 7(6):681\u2013687","journal-title":"J Adolesc young adult Oncol"},{"key":"6075_CR23","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s10552-009-9382-3","volume":"20","author":"TH Keegan","year":"2009","unstructured":"Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL (2009) Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control 20:1881\u20131892","journal-title":"Cancer Causes Control"},{"issue":"2","key":"6075_CR24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/1055-9965.EPI-15-0756","volume":"25","author":"TH Keegan","year":"2016","unstructured":"Keegan TH, DeRouen MC, Parsons HM, Clarke CA, Goldberg D, Flowers CR et al (2016) Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin Lymphoma: A population-based study disparities in HL Survival. Cancer Epidemiol Biomarkers Prev 25(2):264\u2013273","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"6075_CR25","doi-asserted-by":"crossref","first-page":"pkz031","DOI":"10.1093\/jncics\/pkz031","volume":"3","author":"DJ Moke","year":"2019","unstructured":"Moke DJ, Tsai K, Hamilton AS, Hwang A, Liu L, Freyer DR et al (2019) Emerging cancer survival trends, disparities, and priorities in adolescents and young adults: A California cancer registry-based study. JNCI Cancer Spectr 3(2):pkz031","journal-title":"JNCI Cancer Spectr"},{"issue":"11","key":"6075_CR26","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/bloodadvances.2022009225","volume":"7","author":"N Epperla","year":"2023","unstructured":"Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ et al (2023) Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv 7(11):2287\u20132296","journal-title":"Blood Adv"},{"issue":"9","key":"6075_CR27","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1055-9965.EPI-12-0466","volume":"21","author":"CR Flowers","year":"2012","unstructured":"Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW et al (2012) Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 21(9):1520\u20131530","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"6075_CR28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.7326\/0003-4819-141-3-200408030-00012","volume":"141","author":"SH Kaplan","year":"2004","unstructured":"Kaplan SH, Greenfield S (2004) The Patient\u2019s role in reducing disparities. Ann Intern Med 141(3):222\u2013223","journal-title":"Ann Intern Med"},{"issue":"3","key":"6075_CR29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-141-3-200408030-00011","volume":"141","author":"R Lavizzo-Mourey","year":"2004","unstructured":"Lavizzo-Mourey R, Lumpkin JR (2004) From unequal treatment to quality care. Ann Intern Med 141(3):221","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"6075_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10552-005-0487-z","volume":"16","author":"N Hayes","year":"2005","unstructured":"Hayes N, Rollins R, Weinberg A, Brawley O, Baquet C, Kaur JS et al (2005) Cancer-related disparities: weathering the perfect storm through comprehensive cancer control approaches. Cancer Causes Control 16(Suppl 1):41\u201350","journal-title":"Cancer Causes Control"},{"issue":"4","key":"6075_CR31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","volume":"41","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil LJ, Bartlett NL (2023) Navigating the evolving treatment landscape of diffuse large B-Cell Lymphoma. J Clin Oncol 41(4):903\u2013913","journal-title":"J Clin Oncol"},{"issue":"7","key":"6075_CR32","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM et al (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21(7):978\u2013988","journal-title":"Lancet Oncol"},{"issue":"26","key":"6075_CR33","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"1","key":"6075_CR34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2018) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"14","key":"6075_CR35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V et al (2023) Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141(14):1675\u20131684","journal-title":"Blood"},{"issue":"2","key":"6075_CR36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A et al (2023) Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 389(2):148\u2013157","journal-title":"N Engl J Med"},{"issue":"10254","key":"6075_CR37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"2","key":"6075_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M et al (2020) Polatuzumab Vedotin in relapsed or refractory diffuse large B-Cell Lymphoma. J Clin Oncol 38(2):155\u2013165","journal-title":"J Clin Oncol"},{"issue":"4","key":"6075_CR39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab Vedotin in previously untreated diffuse large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"6","key":"6075_CR40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790\u2013800","journal-title":"Lancet Oncol"},{"issue":"24","key":"6075_CR41","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G et al (2022) Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med 387(24):2220\u20132231","journal-title":"N Engl J Med"},{"issue":"12","key":"6075_CR42","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D et al (2023) Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial. J Clin Oncol 41(12):2238\u20132247","journal-title":"J Clin Oncol"},{"key":"6075_CR43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","volume":"35","author":"JM Unger","year":"2016","unstructured":"Unger JM, Cook E, Tai E, Bleyer A (2016) The role of clinical trial participation in cancer research: Barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 35:185\u2013198","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"6075_CR44","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/djq291","volume":"102","author":"JF Scoggins","year":"2010","unstructured":"Scoggins JF, Ramsey SD (2010) A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst 102(17):1371","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"6075_CR45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2023020052","volume":"142","author":"M Casey","year":"2023","unstructured":"Casey M, Odhiambo L, Aggarwal N, Shoukier M, Islam KM, Cortes J (2023) Representation of the population in need for pivotal clinical trials in lymphomas. Blood 142(9):846\u2013855","journal-title":"Blood"},{"issue":"22","key":"6075_CR46","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720\u20132726","journal-title":"JAMA"},{"issue":"16suppl","key":"6075_CR47","doi-asserted-by":"crossref","first-page":"7571","DOI":"10.1200\/JCO.2022.40.16_suppl.7571","volume":"40","author":"FL Locke","year":"2022","unstructured":"Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB et al (2022) Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity. J Clin Oncol 40(16suppl):7571","journal-title":"J Clin Oncol"},{"issue":"15","key":"6075_CR48","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1002\/cncr.32866","volume":"126","author":"MJ Lee","year":"2020","unstructured":"Lee MJ, Koff JL, Switchenko JM, Jhaney CI, Harkins RA, Patel SP et al (2020) Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. Cancer 126(15):3493\u20133503","journal-title":"Cancer"},{"issue":"4","key":"6075_CR49","doi-asserted-by":"crossref","first-page":"708","DOI":"10.5114\/aoms.2015.53289","volume":"11","author":"M Y\u0131ld\u0131r\u0131m","year":"2015","unstructured":"Y\u0131ld\u0131r\u0131m M, Kaya V, Demirpen\u00e7e \u00d6, Payda\u015f S (2015) The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Archives Med Sci 11(4):708\u2013714","journal-title":"Archives Med Sci"},{"issue":"5","key":"6075_CR50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1053\/j.seminoncol.2009.07.009","volume":"36","author":"SM Jaglowski","year":"2009","unstructured":"Jaglowski SM, Linden E, Termuhlen AM, Flynn JM (2009) Lymphoma in adolescents and young adults. Semin Oncol 36(5):381\u2013418","journal-title":"Semin Oncol"},{"issue":"2","key":"6075_CR51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u2009+\u2009B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116","journal-title":"Lancet Oncol"},{"issue":"14","key":"6075_CR52","first-page":"3276","volume":"119","author":"C M\u00fcller","year":"2012","unstructured":"M\u00fcller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S et al (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL Blood. J Am Soc Hematol 119(14):3276\u20133284","journal-title":"J Am Soc Hematol"},{"issue":"23","key":"6075_CR53","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135(23):2041\u20132048","journal-title":"Blood"},{"issue":"1","key":"6075_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-153","volume":"9","author":"R Sharma","year":"2009","unstructured":"Sharma R, Cunningham D, Smith P, Robertson G, Dent O, Clarke SJ (2009) Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients\u2013analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer 9(1):1\u201310","journal-title":"BMC Cancer"},{"issue":"16","key":"6075_CR55","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, Jais J-P, Habermann TM, Thompson CA et al (2018) Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse Large B-Cell Lymphoma and Has implication for bias in clinical trials. J Clin Oncol 36(16):1603\u20131610","journal-title":"J Clin Oncol"},{"issue":"4","key":"6075_CR56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15224","volume":"181","author":"AJ Olszewski","year":"2018","unstructured":"Olszewski AJ, Ollila T, Reagan JL (2018) Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol 181(4):495\u2013504","journal-title":"Br J Haematol"},{"issue":"1","key":"6075_CR57","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1038\/s41598-021-82615-4","volume":"11","author":"M Yoshida","year":"2021","unstructured":"Yoshida M, Nakaya Y, Shimizu K, Tatsumi N, Tsutsumi M, Fuseya H et al (2021) Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma. Sci Rep 11(1):2837","journal-title":"Sci Rep"},{"key":"6075_CR58","doi-asserted-by":"crossref","first-page":"942122","DOI":"10.3389\/fonc.2022.942122","volume":"12","author":"S Xie","year":"2022","unstructured":"Xie S, Yu Z, Feng A, Zheng S, Li Y, Zeng Y et al (2022) Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method. Front Oncol 12:942122","journal-title":"Front Oncol"},{"issue":"47","key":"6075_CR59","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.15585\/mmwr.mm6747a4","volume":"67","author":"M Adakai","year":"2018","unstructured":"Adakai M, Sandoval-Rosario M, Xu F, Aseret-Manygoats T, Allison M, Greenlund KJ et al (2018) Health disparities among American Indians\/Alaska Natives\u2014Arizona, 2017. Morb Mortal Wkly Rep 67(47):1314","journal-title":"Morb Mortal Wkly Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06075-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:13:21Z","timestamp":1735866801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06075-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6075"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06075-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}